These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 24682550

  • 1. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
    Hong YA, Lim JH, Kim MY, Kim Y, Yang KS, Chung BH, Chung S, Choi BS, Yang CW, Kim YS, Chang YS, Park CW.
    Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
    [Abstract] [Full Text] [Related]

  • 2. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C, Cheng C, Wang J, Zhang L, Purrunsing Y, Yang G, Zeng M, Huang H, Ren W, Ye Y, Ma H, Xing C, Wang N.
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [Abstract] [Full Text] [Related]

  • 3. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption.
    Phelps KR, Mason DL.
    Am J Nephrol; 2018 Feb; 47(5):343-351. PubMed ID: 29779023
    [Abstract] [Full Text] [Related]

  • 4. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, Serra AL.
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [Abstract] [Full Text] [Related]

  • 5. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
    Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M.
    Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
    [Abstract] [Full Text] [Related]

  • 6. Disordered FGF23 and mineral metabolism in children with CKD.
    Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB.
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):344-53. PubMed ID: 24311704
    [Abstract] [Full Text] [Related]

  • 7. Chronic Kidney Disease-Mineral Bone Disorder in Korean Patients: a Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).
    Kim CS, Bae EH, Ma SK, Han SH, Lee KB, Lee J, Oh KH, Chae DW, Kim SW, KNOW-CKD Study Group.
    J Korean Med Sci; 2017 Feb; 32(2):240-248. PubMed ID: 28049234
    [Abstract] [Full Text] [Related]

  • 8. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M, Komaba H, Fukagawa M.
    Contrib Nephrol; 2013 Feb; 180():110-23. PubMed ID: 23652554
    [Abstract] [Full Text] [Related]

  • 9. Osteo-renal regulation of systemic phosphate metabolism.
    Razzaque MS.
    IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
    [Abstract] [Full Text] [Related]

  • 10. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.
    Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Obi Y, Okada N, Tsubakihara Y, Isaka Y, Rakugi H.
    Clin J Am Soc Nephrol; 2012 May; 7(5):810-9. PubMed ID: 22362065
    [Abstract] [Full Text] [Related]

  • 11. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD].
    Komaba H.
    Clin Calcium; 2010 Jul; 20(7):1028-36. PubMed ID: 20585181
    [Abstract] [Full Text] [Related]

  • 12. Abnormalities in renal tubular phosphate handling in children with sickle cell disease.
    Raj VM, Freundlich M, Hamideh D, Alvarez O, Seeherunvong W, Abitbol C, Katsoufis C, Chandar J, Ruiz P, Zilleruelo G.
    Pediatr Blood Cancer; 2014 Dec; 61(12):2267-70. PubMed ID: 25132581
    [Abstract] [Full Text] [Related]

  • 13. Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism.
    Sakan H, Nakatani K, Asai O, Imura A, Tanaka T, Yoshimoto S, Iwamoto N, Kurumatani N, Iwano M, Nabeshima Y, Konishi N, Saito Y.
    PLoS One; 2014 Dec; 9(1):e86301. PubMed ID: 24466013
    [Abstract] [Full Text] [Related]

  • 14. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW.
    Am J Nephrol; 2019 Dec; 49(4):284-293. PubMed ID: 30878999
    [Abstract] [Full Text] [Related]

  • 15. In vivo evidence for an interplay of FGF23/Klotho/PTH axis on the phosphate handling in renal proximal tubules.
    Ide N, Ye R, Courbebaisse M, Olauson H, Densmore MJ, Larsson TE, Hanai JI, Lanske B.
    Am J Physiol Renal Physiol; 2018 Nov 01; 315(5):F1261-F1270. PubMed ID: 29993278
    [Abstract] [Full Text] [Related]

  • 16. Differential Determinants of Tubular Phosphate Reabsorption: Insights on Renal Excretion of Phosphates in Kidney Disease.
    Tabibzadeh N, Mentaverri R, Daroux M, Mesbah R, Delpierre A, Paul JG, Deken V, Massy ZA, Bataille P.
    Am J Nephrol; 2018 Nov 01; 47(5):300-303. PubMed ID: 29779025
    [Abstract] [Full Text] [Related]

  • 17. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function.
    Dhayat NA, Ackermann D, Pruijm M, Ponte B, Ehret G, Guessous I, Leichtle AB, Paccaud F, Mohaupt M, Fiedler GM, Devuyst O, Pechère-Bertschi A, Burnier M, Martin PY, Bochud M, Vogt B, Fuster DG.
    Kidney Int; 2016 Sep 01; 90(3):648-57. PubMed ID: 27370409
    [Abstract] [Full Text] [Related]

  • 18. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
    Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG.
    J Clin Invest; 2012 Jul 01; 122(7):2543-53. PubMed ID: 22728934
    [Abstract] [Full Text] [Related]

  • 19. Phosphate homeostasis, parathyroid hormone, and fibroblast growth factor 23 in stages 3 and 4 chronic kidney disease.
    Phelps KR, Mason DL, Stote KS.
    Clin Nephrol; 2016 May 01; 85(5):251-61. PubMed ID: 26951967
    [Abstract] [Full Text] [Related]

  • 20. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E, Yoshida M, Sasaki S.
    BMC Nephrol; 2012 Sep 26; 13():122. PubMed ID: 23013306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.